Pharma giant Biogen and its Japanese partner Eisai have made the decision to halt two phase 3 trials of aducanumab, a drug created to slow Alzheimer’s by targeting brain-destroying beta-amyloid fragments. An independent monitoring committee decided that the drug was unlikely to benefit patients compared with a placebo.
Search results for alzheimer's - 83 results
APP, the gene responsible for making beta-amyloid in the brain, may be able to reshuffle its own DNA, scientists from Sanford Burnham Prebys Medical Discovery Institute in California have claimed. This development could explain why most drugs to treat Alzheimer’s, which are designed to remove beta-amyloid protein build-ups in the brain, have proven ineffective in clinical trials.
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer’s disease, according to research that scientists say may pave the way to a clinical trial.
New technology reveals DNA in neurons is ‘mixed and matched,’ producing thousands of previously unknown gene variations — and identifying a potential near-term treatment for Alzheimer’s disease
New research presented this week at the Alzheimer’s Association International Conference (AAIC) 2018, is suggesting that the liver could be contributing to Alzheimer’s risk by failing to supply key lipids to the brain.
The National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) will begin making large-scale DNA sequence data available to investigators.
Personalised medicine has been a goal of researchers and doctors for a long time. Now, researchers have developed what they call a personalised Therapeutic Intervention Fingerprint (pTIF), for patients with neurological disease.
Scientists have discovered a “big bang” of Alzheimer’s disease — the precise point at which a healthy protein becomes toxic but has not yet formed deadly tangles in the brain.
Tiny snippets of genetic material called microRNA may offer a way to detect conditions such as Alzheimer’s disease earlier, according to a new study.
Alzheimer’s drug development tends to focus on protein aggregates in the brain. Perhaps that’s why they’ve all failed.
An international research team has identified three new genes linked to the risk of Alzheimer’s disease.
Results of an international collaboration report a new association between the PM20D1 gene and Alzheimer’s disease (AD).
Researchers at the RIKEN Center for Brain Science have discovered a mutation that can protect against Alzheimer’s disease in mice.
Researchers have proposed a radical change in the way Alzheimer’s disease is defined, focusing on biological changes in the body, rather than clinical symptoms such as memory loss and cognitive decline.
There is, as of yet, no cure for Alzheimer’s, but a new blood test could open the door to new avenues in drug discovery.